Clinical Trial Update: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ibodutant for irritable bowel syndrome with diarrhea in women has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Diarrhea

Drugs mentioned

• ibodutant (ibodutant)

Snippet

Sponsor: Menarini Group | Conditions: Irritable Bowel Syndrome With Diarrhea | Phase 3 | Status: WITHDRAWN